


CLAIMS

1. (Amended) A compound represented by the following formula (I):



Wherein,

[X is CO , SO_2 or $(\text{CH}_2)_n$ (where n is an integer of 1 to 5, inclusive);]

R_1 is hydrogen, alkyl or alkanoyl;

R_2 is hydrogen or alkyl;

R_3 is hydrogen or an acetoxy group provided that,

when R_3 is hydrogen, X is SO_2 or $(\text{CH}_2)_n$ (wherein, n is an integer of 2 to 5, inclusive), and R_4 is a phenyl group which is unsubstituted or substituted with one or more of the groups consisting of nitro, halogen, haloalkyl, and $\text{C}_1\text{-C}_5$ alkoxy

when R_3 is an acetoxy group, X is CO , SO_2 or $(\text{CH}_2)_n$, (wherein, n is an integer of 1 to 5, inclusive); and R_4 is a phenyl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, haloalkyl, and $\text{C}_1\text{-C}_5$ alkoxy;

or a pharmaceutically-acceptable salt thereof.

Appendix A: Marked-up Copy of Claims

2. (Amended) A compound according to Claim 1, wherein

[X is CO, SO₂ or (CH₂)_n (where n is an integer of 1 – 5, inclusive);]

R₁ is hydrogen, C₁-C₅ alkyl or C₂-C₅ alkanoyl;

R₂ is hydrogen or C₁-C₅ alkyl;

R₃ is hydrogen or an acetoxy group;

when R₃ is hydrogen, X is SO₂ or (CH₂)_n, (wherein, n is an integer of 2 to 5, inclusive), and R₄ is a phenyl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, haloalkyl, and C₁-C₅ alkoxy

When R₃ is an acetoxy group, X is CO, SO₂ or (CH₂)_n, (wherein, n is an integer of 1 to 5, inclusive), and R₄ is a phenyl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, haloalkyl, and C₁-C₅ alkoxy

or a pharmaceutically-acceptable salt thereof.

3. (Amended) A compound according to Claim 1, wherein

[X is CO, SO₂ or (CH₂)_n (where n = 1,2,3);]

R₁ is hydrogen, C₁-C₃ alkyl or C₂-C₃ alkanoyl;

R₂ is hydrogen or C₁-C₃ alkyl;

R₃ is hydrogen or an acetoxy group; and

when R₃ is hydrogen, X is SO₂ or (CH₂)_n, (wherein, n is an integer of 2 to 5, inclusive), and R₄ is a phenyl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, haloalkyl, and C₁-C₅ alkoxy

when R₃ is an acetoxy group, X is CO, SO₂ or (CH₂)_n, (wherein, n is an integer of 1 to 5, inclusive); and R₄ is a phenyl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, haloalkyl, and C₁-C₅ alkoxy


or a pharmaceutically-acceptable salt thereof.

Appendix A: Marked-up Copy of Claims

4. (Amended) A compound according to Claim 1, which is one selected from the group consisting of

[5-(4-nitrobenzyl)aminosalicylic acid ,
(5-(4-chlorobenzyl)aminosalicylic acid ,
(5-(4-trifluoromethylbenzyl)aminosalicylic acid ,
(5-(4-fluorobenzyl)aminosalicylic acid ,
5-(4-methoxybenzyl)aminosalicylic acid,
5-(pentafluorobenzyl)aminosalicylic acid ,
5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate,]
5-(4-nitrobenzyl)-*N*-acetylamino-2-hydroxy ethylbenzoate,
5-(4-nitrobenzyl)-*N*-acetylamino-2-acetoxy ethylbenzoate,
[5-(4-nitrobenzoyl)aminosalicylic acid,
5-(4-nitrobenzenesulfonyl)aminosalicylic acid,]
5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid, and
5-[3-(4-nitrophenyl)-*n*-propyl]aminosalicylic acid,
or a pharmaceutically-acceptable salt thereof.

5. (Amended) A method for protecting central neurons from acute or chronic injuries to the central nervous system (CNS) caused by activation of NMDA glutamate receptors or by entry and accumulation of Zn^{2+} , or by free radicals comprising administering to a patient or a mammal suffering such CNS injuries a therapeutically appropriate amount of a neuroprotective compound [of claim 1] represented by the following formula (I):



Wherein,

X is CO, SO₂ or (CH₂)_n (where n is an integer of 1 to 5, inclusive)

R₁ is hydrogen, alkyl or alkanoyl;


R₂ is hydrogen or alkyl;

R₃ is hydrogen or an acetoxy group; and
R₄ is a phenyl group which is unsubstituted or substituted with
one or more of the group consisting of nitro, halogen, haloalkyl,
and C₁-C₅ alkoxy;

or a pharmaceutical-acceptable salt thereof.

8. (Amended) A method according to Claim [3]5, wherein said compound attenuates NMDA neurotoxicity, Zn²⁺ neurotoxicity, and blocks free radical neurotoxicity as a direct antioxidant.

9. (Amended) A [method] composition for treating or preventing neurological diseases [linked to] caused by activation of NMDA [neurotoxicity] glutamate receptors, Zn²⁺ or oxidative stress, comprising administering to a patient or a mammal suffering from [such]said neurological diseases a therapeutically effective amount of [claim 1] the compound represented by the following formula (I):



Wherein,

X is CO, SO₂ or (CH₂)_n (where n is an integer of 1 to 5, inclusive)

R₁ is hydrogen, alkyl or acanoyl;

R₂ is hydrogen or alkyl;

R₃ is hydrogen or an acetoxy group; and

R₄ is a phenyl group which is unsubstituted or substituted with
one or more of the group consisting of nitro, halogen, haloalkyl,
and C₁-C₅ alkoxy; or a pharmaceutical-acceptable salt thereof.